Home / Knowledge Center /
Poster

DNA Damage Response Deficiency (DDRD) in Breast Cancer is associated with a STING-dependent Innate Immune Response

Key Findings:

  • DNA damage response deficient human breast cancers are associated with CD8+ and CD4+ lymphocytic infiltration.
  • The epithelial component of DDRD tumors releases chemokines that can account for lymphocytic infiltration.
  • Chemokine release is dependent on activation of the cGAS-STING-IRF3 pathway which is constitutively activated in DNA repair deficient cells, or by exogenous DNA damaging agents.
  • Activation of the cGAS-STING-IRF3 pathway is cell cycle specific and is associated with an accumulation of cytosolic DNA in the S-phase of the cell cycle.
  • Activation of the cGAS-STING-IRF3 pathway is associated with expression of the immune-checkpointinggene PD-L1 which may prevent immune-mediated tumorcell death.
  • This may provide a therapeutic rationale for immune-checkpoint targeted therapies in the context of DNA damage response deficiency in cancer.
View Resource
Almac Logo

Diagnostic Services

Your global partner for biomarker discovery, development & commercialization.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialization services.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies